Trials / Recruiting
RecruitingNCT06075563
Total Lymphoid Irradiation as Conditioning for Pediatric Haploidentical Hematopoietic Stem Cell Transplantation
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 23 (estimated)
- Sponsor
- Hong Kong Children's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this comparative study, the investigators aim to compare prospective pediatric patients who receive total lymphoid irradiation (TLI) using tomotherapy with age- and disease-matched controls who receive conventional total body irradiation (TBI) as part of conditioning for haploidentical hematopoietic stem cell transplantation (HSCT) for both malignant and non-malignant diseases. The investigators shall evaluate graft failure-free, graft-versus-host disease (GVHD)-free survival, overall survival, frequency of rejection, GVHD, relapse of malignancy, adverse effects and post-transplant immunoreconstitution.
Detailed description
Radiotherapy at a dose of 6Gy divided into 3 equal fractions (2Gy per fraction) to all lymphoid organs (TLI) over 2 days using tomotherapy will be given to participants as part of the conditioning treatment before haploidentical hematopoietic stem cell transplantation (HSCT). Retrospective patients who are age- and disease-matched with the recruited patients and had received radiotherapy to the whole body (TBI) with or without lung shielding at a total dose of 2-12 Gy delivered as 1-6 equal fractions by conventional opposed fields radiotherapy as part of conditioning will be compared for the outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Total lymphoid irradiation | Total lymphoid irradiation (TLI) 6Gy by tomotherapy as part of conditioning treatment before haploidentical hematopoietic stem cell transplant |
Timeline
- Start date
- 2023-05-29
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2023-10-10
- Last updated
- 2025-09-10
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT06075563. Inclusion in this directory is not an endorsement.